Excepteur sint occaecat curidatat non kroident sunt in cunpa quisa.
GI Cryo, Inc. is a start-up medtech company focused on the development of minimally-invasive cryoablation devices for the treatment of pancreatic cancer and other gastroenterological based diseased tissue. GI Cryo has licensed a novel ablation platform which includes the GastroCS cryoengine and FrostBite endoscopic ultrasound compatible cryoablation catheter (FrostBite platform). GI Cryo has assembled a strong team comprised of internationally recognized individuals who have a demonstrated track record in technology development, commercialization, and sales and marketing to spearhead the development and commercialization of the FrostBite platform. Collectively, this team has overseen the development and introduction of several medical devices and disposables in the cryosurgical arena. GI Cryo is now poised to complete engineering design and transition FrostBite into clinical trials, regulatory approval and manufacturing in support of commercial distribution once FDA cleared.
Pancreatic cancer strikes millions of individuals annually worldwide. With a 5 year survival rate of less than 5%, today a diagnosis of pancreatic cancer is essentially a death sentence (6-12 month life expectancy) due to no truly effective treatment options. In the United States alone it is estimated by the American Cancer Society that >48,000 new cases will be diagnosed in 2015 with over 40,000 deaths, ranking pancreatic cancer as the 4th leading cause of cancer related deaths in the US. Worldwide, an estimated 330,000 individuals were diagnosed in 2014. Based on current trends and prognoses of continued increases in incidence, it has recently been projected that pancreatic cancer will become the 2nd leading cause of cancer-related deaths in the US by 2030, overtaking both colon and breast cancer and falling below only lung cancer. As such, it is clear that there is a significant need and urgency for the development of new treatments.
GI Cryo, Inc. is a startup company focused on the final development and commercialization of a novel catheter-based, ultrasound guided, endoscopic cryoablation technology platform. The GastroCS System (GastroCS cryoablation console and FrostBite EUS Cryocatheter) has robust intellectual property backing to which GI Cryo has obtained an exclusive license for the use within gastroenterological arena. As related to this initiative, GI Cryo is looking to develop the technology for indication specific use in the GI area, initially focusing on pancreatic cancer.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident sunt in culpa qui officia deserunt.
Primary Indications Pressing Need
Disclaimer: GI Cryo’s technologies are currently Investigational Devices and are limited by Federal Law to Investigational Use Only